SNPX - Synaptogenix, Inc. Stock Price, Fair Value and News

4.80USD+0.09 (+1.91%)Delayed as of 16 May 2024, 12:48 pm ET

Market Summary

USD4.80+0.09

Delayedas of 16 May 2024, 12:48 pm

1.91%

SNPX Stock Price

View Fullscreen

SNPX RSI Chart

SNPX Valuation

Market Cap

5.8M

Price/Earnings (Trailing)

-1.28

Price/Sales (Trailing)

3.38

EV/EBITDA

4.53

Price/Free Cashflow

-1.09

SNPX Price/Sales (Trailing)

SNPX Profitability

EBT Margin

-264.19%

Return on Equity

-20.56%

Return on Assets

-15.42%

Free Cashflow Yield

-91.45%

SNPX Fundamentals

SNPX Revenue

Revenue (TTM)

1.7M

Rev. Growth (Yr)

89.68%

Rev. Growth (Qtr)

-49.92%

SNPX Earnings

Earnings (TTM)

-4.5M

Earnings Growth (Yr)

87.92%

Earnings Growth (Qtr)

79.25%

Breaking Down SNPX Revenue

52 Week Range

4.95

(Low)(High)

Last 7 days

1.3%

Last 30 days

6.6%

Last 90 days

5.4%

Trailing 12 Months

-76.4%

How does SNPX drawdown profile look like?

SNPX Financial Health

Current Ratio

4.58

SNPX Investor Care

Shares Dilution (1Y)

318.90%

Diluted EPS (TTM)

-33.91

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	1.7M	0	0	0
2023	726.8K	1.1M	1.5M	1.6M
2022	30.6K	54.1K	192.3K	335.0K
2021	0	104.5K	55.8K	7.1K
2020	322.3K	266.0K	209.6K	153.2K
2019	0	0	0	378.7K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Synaptogenix, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 16, 2022	alkon daniel l.	sold	-23,072	1.1719	-19,688	president and cso
Dec 16, 2022	bernstein bruce	sold	-26,367	1.1719	-22,500	-
Dec 16, 2022	schechter jonathan	sold	-23,731	1.1719	-20,250	-
Dec 16, 2022	singer william s.	sold	-31,641	1.1719	-27,000	-
Dec 16, 2022	silverman joshua	sold	-22,280	1.1719	-19,012	-
Dec 16, 2022	tuchman alan j	sold	-31,641	1.1719	-27,000	chief executive officer
Dec 16, 2022	weinstein robert	sold	-31,641	1.1719	-27,000	chief financial officer
Jul 13, 2021	perry george	acquired	-	-	40,000	-
Jul 13, 2021	alkon daniel l.	acquired	-	-	43,750	president and cso
Jul 13, 2021	silverman joshua	acquired	-	-	42,250	-

Which funds bought or sold SNPX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 15, 2024	STATE STREET CORP	unchanged	-	-1,696	3,769	-%
May 15, 2024	MORGAN STANLEY	unchanged	-	-193	429	-%
May 15, 2024	FIRST MANHATTAN CO. LLC.	sold off	-100	-6.00	-	-%
May 15, 2024	Tower Research Capital LLC (TRC)	reduced	-73.58	-86.00	19.00	-%
May 15, 2024	TWO SIGMA ADVISERS, LP	sold off	-100	-12,507	-	-%
May 15, 2024	TWO SIGMA SECURITIES, LLC	new	-	15,639	15,639	-%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	sold off	-100	-10,604	-	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	sold off	-100	-11,474	-	-%
May 15, 2024	Royal Bank of Canada	unchanged	-	-	-	-%
May 15, 2024	CITADEL ADVISORS LLC	new	-	15,665	15,665	-%

Are Funds Buying or Selling SNPX?

Are funds buying SNPX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SNPX

No. of Funds

Unveiling Synaptogenix, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 06, 2024	intracoastal capital, llc	4.99%	1,048,214	SC 13G/A
Feb 08, 2023	intracoastal capital, llc	9.99%	786,710	SC 13G/A
Jan 18, 2023	haywood george weaver	0%	0	SC 13G/A
Feb 11, 2022	intracoastal capital, llc	9.99%	740,339	SC 13G/A

Recent SEC filings of Synaptogenix, Inc.

View All Filings

Date Filed	Form Type	Document
May 15, 2024	10-Q	Quarterly Report
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 10, 2024	4	Insider Trading
Apr 04, 2024	8-K	Current Report
Apr 01, 2024	10-K	Annual Report
Feb 06, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Synaptogenix, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	49.5B	6.8B	24.29%	3.18%	-8.29	7.22	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.7B	2.0B	-0.16%	-22.78%	-56.17	9.31	75.20%	68.82%
BMRN	15.3B	2.5B	-12.17%	-12.66%	74.28	6.17	13.74%	186.89%
INCY	12.8B	3.8B	6.79%	-11.81%	17.19	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	16.38%	112.85%	-10.26	48.09	54.84%	-28.31%
APLS	5.1B	524.1M	-18.64%	-52.21%	-12.19	9.71	394.93%	39.61%
AXSM	3.6B	251.0M	11.42%	-1.40%	-12.17	14.37	73.58%	-86.73%
ARWR	3.1B	240.7M	4.29%	-33.48%	-6.61	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-10.48%	-30.90%	-1.5K	3.07	56.43%	98.83%
SMALL-CAP
CPRX	2.0B	411.3M	8.25%	33.17%	30.22	4.78	60.38%	-34.49%
NVAX	1.8B	996.6M	212.62%	68.59%	-4.54	1.81	-26.66%	65.49%
CRBP	472.0M	881.7K	3.39%	323.08%	-13.98	481.06	-77.61%	33.36%
INO	339.4M	4.9M	19.20%	55.95%	-2.72	69.75	-54.97%	48.23%
IBIO	16.2M	2.1M	-2.59%	102.15%	-0.7	7.61	-13.45%	69.54%

Synaptogenix, Inc. News

Latest updates

Synaptogenix, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Revenue	68.2%	463,395	275,439	549,995	427,159	396,357	145,212	140,730	44,487	4,610	2,518	2,445	3,896	5,346	6,797	75,641	70,867	80,513	90,159
Operating Expenses	-20.7%	1,691,494	2,132,408	1,429,792	1,829,713	2,921,941	5,888,867	3,167,206	3,796,391	3,282,532	4,238,563	2,929,378	2,295,173	3,179,707	2,576,406	2,576,406	2,608,211	-	3,914,722
S&GA Expenses	-100.0%	-	1,554,515	1,217,689	1,522,502	2,044,224	4,475,808	1,682,512	1,855,290	1,796,458	2,876,925	2,092,662	1,308,893	1,766,377	1,778,187	2,013,089	2,214,966	-	2,131,205
R&D Expenses	5.4%	609,249	577,893	212,103	307,211	877,717	1,413,059	1,484,694	1,941,101	1,486,074	1,361,638	836,716	986,280	1,607,294	410,292	563,317	393,245	-	845,797
EBITDA Margin	27.9%	-2.64	-3.66	-0.36	-3.91	-5.51	-16.62	-74.28	-262	-416	-1,773	-191	-114	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	79.2%	-206,699	-995,969	763,203	-4,093,954	-1,711,784	4,482,345	-3,026,476	-3,751,904	-3,277,922	-4,236,045	-2,926,933	-2,293,842	-2,295,376	-4,269,609	-4,269,609	-2,537,344	-	-3,824,563
EBT Margin	27.9%	-2.64	-3.66	-0.37	-3.92	-5.51	-16.64	-74.31	-262	-416	-1,773	-191	-114	-	-	-	-	-	-
Net Income	79.2%	-206,699	-995,969	763,203	-4,093,954	-1,711,784	4,482,345	-3,026,476	-3,751,904	-3,277,922	-4,236,045	-2,926,933	-2,293,842	-	-4,269,609	-4,269,609	-2,537,344	-	-3,824,563
Net Income Margin	27.9%	-2.64	-3.66	-0.37	-3.92	-5.51	-16.64	-74.31	-262	-416	-1,773	-227	-121	-	-	-	-	-	-
Free Cashflow	-71.8%	-1,831,541	-1,066,000	-1,171,910	-1,240,156	-1,697,850	-2,785,657	-2,420,484	-2,524,083	-3,485,406	-2,045,166	-1,080,236	-1,998,606	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-5.5%	29,399	31,114	32,360	33,437	36,529	38,608	27,351	29,579	32,353	35,525	32,359	32,960	16,347	6,751	29,150	17,898
Current Assets	-5.6%	28,828	30,533	32,341	33,416	36,507	38,586	27,329	29,558	32,334	35,504	32,340	32,940	16,326	6,729	29,126	17,876
Cash Equivalents	-8.3%	26,330	28,700	31,700	32,899	35,800	37,500	26,334	28,755	2,863	34,214	31,295	31,702	14,848	5,795	27,000	17,382
Net PPE	-7.6%	17.00	19.00	20.00	21.00	22.00	22.00	22.00	21.00	19.00	20.00	18.00	20.00	21.00	22.00	23.00	22.00
Liabilities	18.0%	6,523	5,529	3,932	6,530	2,343	3,193	-	-	-	1,995	-	-	-	-	-	-
Current Liabilities	47.3%	6,300	4,276	1,818	2,773	1,277	1,313	684	626	669	1,995	1,007	770	937	1,612	1,300	479
Shareholder's Equity	-9.4%	22,053	24,347	26,741	24,830	31,464	32,693	26,667	28,953	31,684	33,530	31,351	32,190	15,409	5,139	-	17,419
Retained Earnings	-1.3%	-34,035	-33,610	-32,381	-32,019	-21,809	-19,831	-24,197	-21,171	-17,419	-14,141	-9,905	-6,978	-4,684	-1,530	-	-
Additional Paid-In Capital	-3.2%	56,089	57,955	59,120	56,849	53,273	52,524	50,864	50,124	49,103	47,671	41,256	39,168	20,093	6,669	-	-
Shares Outstanding	12.6%	1,085	964	700	295	294	291	280	278	278	269	177	142	119	-	-	-
Float	-	-	-	-	6,624	-	-	-	35,194	-	-	-	59,482	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3
Cashflow From Operations	-71.8%	-1,831	-1,066	-1,171	-1,239	-1,695	-2,783	-2,418	-2,524	-3,485	-2,045	-1,080	-1,998	-3,586	-1,205	-3,251	-1,906	-1,738	-	-
Cashflow From Investing	75.0%	-500	-2,000	-	-669*	-2.04	-2.14	-2.25	-	-	-	-	-	-	-	-	-2.81	-2.60	-	-
Cashflow From Financing	100.0%	-	-51*	49*	-	-	13,930	-	-	553	4,968	673	18,852	12,640	-19,999	-	-	16,520	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SNPX Income Statement

2023-12-31

STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	12 Months Ended
STATEMENTS OF COMPREHENSIVE LOSS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
OPERATING EXPENSES:
Research and development	$ 1,974,924	$ 6,324,928
General and administrative	6,338,930	9,810,068
TOTAL OPERATING EXPENSES	8,313,854	16,134,996
OTHER INCOME:
Interest income	1,648,950	335,039
Change in fair value of warrant liability	1,370,000	8,405,000
Change in fair value of derivative liability	(743,600)	1,821,000
TOTAL OTHER INCOME	2,275,350	10,561,039
Net loss before income taxes	(6,038,504)	(5,573,957)
Net loss	(6,038,504)	(5,573,957)
Preferred Stock dividends	2,047,774	115,890
Deemed dividend-preferred stock extinguishment	5,693,000
Net Loss attributable to common stockholders	(13,779,278)	(5,689,847)
Change in fair value of available for sale debt security	902
Net comprehensive loss	$ (13,778,376)	$ (5,689,847)
PER SHARE DATA:
Basic loss per common share (in dollars per share)	$ (1.18)	$ (0.81)
Diluted loss per common share (in dollars per share)	$ (1.18)	$ (0.81)
Basic weighted average common shares outstanding (in shares)	11,651,900	6,989,200
Diluted weighted average common shares outstanding (in shares)	11,651,900	6,989,200

SNPX Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($)	Dec. 31, 2023	Dec. 31, 2022
CURRENT ASSETS
Cash and cash equivalents	$ 28,661,498	$ 37,478,480
Prepaid Clinical trial expenses	375,085	367,714
Available for sale debt security	1,438,500
Prepaid expenses and other current assets	57,677	739,467
TOTAL CURRENT ASSETS	30,532,760	38,585,661
Equity method investment	562,402
Fixed assets, net of accumulated depreciation	18,505	22,145
TOTAL ASSETS	31,113,667	38,607,806
CURRENT LIABILITIES
Accounts payable	444,633	660,206
Accrued expenses	435,891	536,714
Dividends payable		115,890
Accrued Series B Convertible Preferred payments payable	3,395,945
TOTAL CURRENT LIABILITIES	4,276,469	1,312,810
Warrant liability	140,000	1,510,000
Derivative liability	1,113,000	370,300
TOTAL LIABILITIES	5,529,469	3,193,110
Commitments and contingencies
Series B Convertible redeemable preferred stock, $.0001 par value and $1,000 face value, 1,000,000 shares authorized; 6,000 and 15,000 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively. Liquidation preference of $6,000,000 plus dividends accrued at 7% per annum of $140,000 as of December 31, 2023.	1,236,940	2,721,723
STOCKHOLDERS' EQUITY
Common stock - 150,000,000 shares authorized, $0.0001 par value; 24,089,646 shares issued and outstanding as of December 31, 2023 and 7,267,032 shares issued and outstanding as of December 31, 2022.	2,411	728
Additional paid-in capital	57,954,693	52,523,762
Accumulated other comprehensive income	902
Accumulated deficit	(33,610,748)	(19,831,517)
TOTAL STOCKHOLDERS' EQUITY	24,347,258	32,692,973
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 31,113,667	$ 38,607,806

About Synaptogenix, Inc.

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.

CEO	Dr. Alan J. Tuchman M.D., MBA(FAAN)
WEBSITE	synaptogen.com
INDUSTRY	Biotechnology
EMPLOYEES	5

Synaptogenix, Inc. Frequently Asked Questions

What is the ticker symbol for Synaptogenix, Inc.? What does SNPX stand for in stocks?

SNPX is the stock ticker symbol of Synaptogenix, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Synaptogenix, Inc. (SNPX)?

As of Wed May 15 2024, market cap of Synaptogenix, Inc. is 5.81 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNPX stock?

You can check SNPX's fair value in chart for subscribers.

What is the fair value of SNPX stock?

You can check SNPX's fair value in chart for subscribers. The fair value of Synaptogenix, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Synaptogenix, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SNPX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Synaptogenix, Inc. a good stock to buy?

The fair value guage provides a quick view whether SNPX is over valued or under valued. Whether Synaptogenix, Inc. is cheap or expensive depends on the assumptions which impact Synaptogenix, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNPX.

What is Synaptogenix, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed May 15 2024, SNPX's PE ratio (Price to Earnings) is -1.28 and Price to Sales (PS) ratio is 3.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNPX PE ratio will change depending on the future growth rate expectations of investors.